p. 10045−10051
2476-762X
Vol.15/No.23
p. 10053−10056
2476-762X
Vol.15/No.23
p. 10057−10059
2476-762X
Vol.15/No.23
p. 10061−10066
2476-762X
Vol.15/No.23
p. 10067−10070
2476-762X
Vol.15/No.23
p. 10071−10077
2476-762X
Vol.15/No.23
p. 10079−10083
2476-762X
Vol.15/No.23
p. 10085−10089
2476-762X
Vol.15/No.23
p. 10091−10094
2476-762X
Vol.15/No.23
p. 10095−10099
2476-762X
Vol.15/No.23
p. 10101−10106
2476-762X
Vol.15/No.23
p. 10107−10114
2476-762X
Vol.15/No.23
p. 10115−10119
2476-762X
Vol.15/No.23
0.4) and favorable discriminant validity (item own scalecorrelation >0.8). There was no correlation between In-patsat32 scales and the EORTC-C30, which measuresdifferent concepts, confirming divergent validity of the tool. Internal consistency for all domains was high (α>0.70)except for the hospital access score and the test-retest reliability was excellent (r=0.86-0.96). There was a weakresponsiveness to change except for nurses technical skills. Principle component analysis confirmed five domainswith much improved internal consistency (α>0.9). Conclusions: The Persian version of the EORTC-in-patsat32module is a reliable and valid instrument to measure cancer patient satisfaction with care received during theirhospitalization period and can be utilized in clinical cancer research.]]>
p. 10121−10128
2476-762X
Vol.15/No.23
p. 10129−10135
2476-762X
Vol.15/No.23
p. 10137−10142
2476-762X
Vol.15/No.23
p. 10143−10149
2476-762X
Vol.15/No.23
p. 10151−10156
2476-762X
Vol.15/No.23
p. 10157−10164
2476-762X
Vol.15/No.23
p. 10165−10169
2476-762X
Vol.15/No.23
p. 10171−10174
2476-762X
Vol.15/No.23
p. 10175−10179
2476-762X
Vol.15/No.23
p. 10181−10185
2476-762X
Vol.15/No.23
p. 10187−10192
2476-762X
Vol.15/No.23
p. 10193−10198
2476-762X
Vol.15/No.23
p. 10199−10207
2476-762X
Vol.15/No.23
p. 10209−10215
2476-762X
Vol.15/No.23
p. 10217−10223
2476-762X
Vol.15/No.23
p. 10225−10229
2476-762X
Vol.15/No.23
p. 10231−10236
2476-762X
Vol.15/No.23
p. 10237−10240
2476-762X
Vol.15/No.23
p. 10241−10244
2476-762X
Vol.15/No.23
p. 10245−10250
2476-762X
Vol.15/No.23
p. 10251−10254
2476-762X
Vol.15/No.23
p. 10255−10262
2476-762X
Vol.15/No.23
38.5°C or two consecutive readings of >38.0°C for 2 hours and an absolute neutrophil count<0.5x109/L, or expected to fall below 0.5x109/L (de Naurois et al, 2010). TRD was defined as death occurringduring or within 30 days of the last chemotherapy treatment, as a consequence of the chemotherapy treatment.Statistical analysis was performed using the SPSS version 18.0 software. Survival probabilities were estimatedusing the Kaplan-Meier method and differences in survival compared using log-rank test. Results: Between 1stJanuary 2002 and 31st December 2011, 424 patients with MBC were treated in UMMC. A total of 186 out of221 patients with de novo MBC who received first line palliative chemotherapy were analyzed. The mean ageof patients in this study was 49.5 years (range 24 to 74 years). Biologically, ER status was negative in 54.4%of patients and Her-2 status was positive in 31.1%. A 5-flourouracil, epirubicin and cyclophosphamide (FEC)chemotherapy regimen was chosen for 86.6% of the cases. Most patients had multiple metastatic sites (58.6%).The main result of this study showed a FN rate of 5.9% and TRD rate of 3.2%. The median survival (MS) forthe entire cohort was 19 months. For those with multiple metastatic sites, liver only, lung only, bone only andbrain only metastatic sites, the MS was 18, 24, 19, 24 and 8 months respectively (p-value= 0.319). Conclusions:In conclusion, we surmise that FEC is a safe regimen with acceptable FN and TRD rates for de novo MBC.]]>
p. 10263−10266
2476-762X
Vol.15/No.23
p. 10267−10272
2476-762X
Vol.15/No.23
p. 10273−10276
2476-762X
Vol.15/No.23
p. 10277−10280
2476-762X
Vol.15/No.23
p. 10281−10287
2476-762X
Vol.15/No.23
p. 10289−10292
2476-762X
Vol.15/No.23
p. 10293−10298
2476-762X
Vol.15/No.23
p. 10299−10306
2476-762X
Vol.15/No.23
p. 10307−10311
2476-762X
Vol.15/No.23
p. 10313−10317
2476-762X
Vol.15/No.23
p. 10319−10323
2476-762X
Vol.15/No.23
p. 10325−10328
2476-762X
Vol.15/No.23
p. 10329−10334
2476-762X
Vol.15/No.23
p. 10335−10338
2476-762X
Vol.15/No.23
p. 10339−10343
2476-762X
Vol.15/No.23
p. 10345−10350
2476-762X
Vol.15/No.23
p. 10351−10354
2476-762X
Vol.15/No.23
p. 10355−10361
2476-762X
Vol.15/No.23
p. 10363−10366
2476-762X
Vol.15/No.23
p. 10367−10374
2476-762X
Vol.15/No.23
p. 10375−10379
2476-762X
Vol.15/No.23
p. 10381−10385
2476-762X
Vol.15/No.23
p. 10387−10391
2476-762X
Vol.15/No.23
p. 10393−10396
2476-762X
Vol.15/No.23
p. 10397−10400
2476-762X
Vol.15/No.23
p. 10401−10405
2476-762X
Vol.15/No.23
p. 10407−10412
2476-762X
Vol.15/No.23
p. 10413−10420
2476-762X
Vol.15/No.23
p. 10421−10425
2476-762X
Vol.15/No.23
40 years) werethe main identifiable risk factors. Patients with OPMDs displayed a general lack of awareness and negativeattitudes towards early diagnosis and treatment. Conclusions: OPMDs among Arab dental patients are relativelyuncommon and awareness about oral cancer among Jordanian dental patients is low. Interventions to improvepublic knowledge about oral cancer and attitudes toward early diagnosis and treatment are urgently indicated.]]>
p. 10427−10431
2476-762X
Vol.15/No.23
p. 10433−10438
2476-762X
Vol.15/No.23
p. 10439−10444
2476-762X
Vol.15/No.23
0.05). Baseline pain score of patients with moderate pain in treatment and control group was 4.9±0.8 and5.1±0.8, respectively; and decreased to 1.8±1.1 and 1.2±1.1 after treatment, respectively. Pain intensity wassignificantly reduced in the treatment group (P =0.028). Average daily consumption of oxycodone prolongedreleasetablets was (54.0±19.6) mg and (44.7± 18.7) mg respectively, which is lower in treatment grpup than incontrol group, but the difference was not statistically significant (P=0.065). Baseline pain score of patients withsevere pain in treatment and control groups were 8.3±1.1 and 8.3±1.1, respectively; and pain intensity aftertreatment decreased to 2.9±1.0 and 2.3±1.0. Pain intensity was significantly reduced in the treatment group,with statistical significance (P =0.026). Average daily consumption of oxycodone prolonged-release tablets was(132.0±42.2) mg and (110.7±33.9) mg, respectively, which is lower in treatment group than in control group, andthe difference was statistically significant (P=0.035). In terms of quality of life, patients in treatment group hadbetter performance status, daily activity, mood, and sleep than that in control group (P < 0.05). Patients in twogroups had similar side effects, eg., constipation, nausea/vomiting, lethargy, dizziness, itchy skin, dysuria, andataxia. Lower incidence of nausea/vomiting, lethargy, was obtained from patients in treatment than in controlgroup, while significant low constipation was observed in treatment than in control group (35.0% vs 49.2%,P=0.026). Conclusion: Fluvoxamine combined with oxycodone prolonged-release tablets could be more effectivein treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets andthus be associated with lower side effects, and improved quality of life.]]>
p. 10445−10449
2476-762X
Vol.15/No.23
p. 10451−10456
2476-762X
Vol.15/No.23
p. 10457−10462
2476-762X
Vol.15/No.23
p. 10463−10468
2476-762X
Vol.15/No.23
p. 10469−10473
2476-762X
Vol.15/No.23
p. 10475−10481
2476-762X
Vol.15/No.23
p. 10483−10487
2476-762X
Vol.15/No.23
p. 10489−10493
2476-762X
Vol.15/No.23
p. 10495−10500
2476-762X
Vol.15/No.23
p. 10501−10504
2476-762X
Vol.15/No.23
p. 10505−10508
2476-762X
Vol.15/No.23
0.05). Conclusions: Mostly locatedin adrenal areas and with vascular embedding as a primary manifestation, the neuroblastoma extremely readilymetastases to lymph nodes and other organs as well as infiltrating local tissues, with dilation on angiographyfrequent in or around the tumors. With vascular displacement as a primary manifestation, ganglioneuroblastomahas a regular morphology and clear boundaries.]]>
p. 10509−10512
2476-762X
Vol.15/No.23
p. 10513−10524
2476-762X
Vol.15/No.23
p. 10525−10529
2476-762X
Vol.15/No.23
p. 10531−10537
2476-762X
Vol.15/No.23
p. 10539−10542
2476-762X
Vol.15/No.23